Climb Bio, Inc. (CLYM) Reports Early Phase 2 Signals in pMN

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

Climb Bio (CLYM) presented Phase 2 data for budoprutug, its anti-CD19 mAb, at ASN Kidney Week. The 200 mg dose showed B-cell depletion, PLA2R Ab reduction, and immunologic remission in pMN patients. A separate case study reported 3-year steroid-free remission in an MCD patient. Additional data is expected in 2027. The drug was generally well-tolerated.

Climb Bio (CLYM) and Beijing Mabworks reported Phase 1 data showing their anti-APRIL antibody reduced Gd-IgA1 by ~70% and IgA by ~60% at 12 weeks in healthy volunteers. The trials involved 88 participants across Australia and China. The antibody was well-tolerated, with no serious adverse events. The company plans to initiate a Phase 3 trial in 2027, pending regulatory feedback.

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.